ROCKLAND, Mass., April 16, 2015 /PRNewswire/ -- EMD Serono today announced the US biopharmaceutical business of Merck KGaA, Darmstadt, Germany, appointed Alise Reicin, MD, as Senior Vice President, Head of Global Clinical Development. Dr. Reicin brings extensive research and early/late clinical development expertise, including experience in Oncology and Immunology. She is an accomplished pharmaceutical executive with strong leadership ability, having served as a Vice President in various capacities across R&D at MSD (Merck Sharp & Dohme) for the last 10 years.
In her role as Head of Global Clinical Development, Reicin will oversee the Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she will lead the biopharmaceutical business of Merck KGaA, Darmstadt, Germany's portfolio of pipeline programs.
"We are honored to have Alise join us," says Luciano Rossetti, Head of Global Research and Development. "Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organization. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating model."
Reicin's experience complements the R&D strategy of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, which focuses on the core therapeutic areas of oncology, immuno-oncology and immunology with several high-priority programs in late development, such as evofosfamide (TH-302) and avelumab (anti-PD-L1), as well as a number of promising early-stage assets.
In the past, Alise served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, she led MSD's PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. She also managed program leaders across early and late oncology product development teams. During her tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.
Before joining MSD, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
Reicin has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).
Reicin will report to Luciano Rossetti, Head of Global R&D, and serve as a member of the R&D Executive Leadership Team. Her official start date is on May 11, 2015, and she will be based in Billerica, MA.
EMD Serono
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading US biopharmaceutical company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com
Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials and generated sales of 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
Cory Tromblee
Phone: 781.681.2393
Photo - http://photos.prnewswire.com/prnh/20150415/198968
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alise-reicin-joins-the-biopharmaceutical-business-of-merck-kgaa-darmstadt-germany-as-head-of-global-clinical-development-300066886.html
SOURCE EMD Serono